Myeloma bone disease: pathophysiology and management. (Q36146493)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15928069%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

review article

1 reference

title

Myeloma bone disease: pathophysiology and management (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15928069%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

1 reference

1 reference

Athanasios Dimopoulos

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15928069%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

author name string

E Terpos

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15928069%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

publication date

31 May 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15928069%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15928069%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15928069%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15928069%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

page(s)

1223-1231

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15928069%20AND%20SRC:MED&resulttype=core&format=json

Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study

12 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI235

IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI235

TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI235

Multiple myeloma cells catalyze hepatocyte growth factor (HGF) activation by secreting the serine protease HGF-activator

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI235

Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI235

Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI235

Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI235

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI235

Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI235

OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI235

osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI235

Interpreting the molecular biology and clinical behavior of multiple myeloma in the context of global gene expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI235

Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI235

Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI235

Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI235

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI235

Bone lesions in molecular subtypes of multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI235

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI235

Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI235

Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI235

Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI235

Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI235

Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI235

Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI235

Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI235

Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI235

Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI235

American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI235

Perspective study on pamidronate in stage I multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI235

Pamidronate increases markers of bone formation in patients with multiple myeloma in plateau phase under interferon-alpha treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI235

Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI235

Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI235

Percutaneous vertebroplasty: indications, contraindications, and technique

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI235

Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI235

A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI235

A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI235

Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI235

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI235

Bisphosphonates in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI235